Strategic Partnerships There is active collaboration with radiopharmacy and CDMOs, evidenced by a June 2025 partnership with TAG1 Inc. This suggests opportunities to position Radiopharmacy as a preferred manufacturing and sourcing partner for isotopes and radiopharmaceuticals across regional and global supply chains.

Expansion Footprint Radiopharmacy has been expanding facility presence in key US regions (Los Angeles and Salt Lake City) in 2024, signaling growth plans and potential demand for supply chain, logistics, and facility services as they scale production capacity and accelerate commercialization.

Leadership Transition Recent CFO departure and a new CEO appointment in mid-2025 indicate a period of strategic realignment and potential emphasis on financial optimization, capital deployment, and partnerships that can drive sales opportunities in treasury management, ERP enhancements, and cost-to-serve improvements.

Tech Enablement Adoption of ERP and enterprise tools (SAP, NetSuite, Coupa, Smartsheet) shows a maturing digital backbone. This creates opportunities to offer integrated procurement, forecasting, and financial analytics solutions or add-ons that improve procurement efficiency and compliance for radiopharmaceutical manufacturing.

Growth Profile Revenue is in the tens of millions with 11-50 employees, and rapid development through acquisitions (Agilera Pharma, stake movements with IFE) implies a high-growth trajectory. Sales focus could target scalable manufacturing services, contract development, and supply chain optimization for expanding radiopharmaceutical production.